Compare · IBO vs NVO
IBO vs NVO
Side-by-side comparison of Impact BioMedical Inc. (IBO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, IBO is down 76.0% and NVO is down 34.2% - NVO leads by 41.7 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for IBO).
- NVO has more recent analyst coverage (25 ratings vs 0 for IBO).
- Company
- Impact BioMedical Inc.
- Novo Nordisk A/S
- Price
- $0.63-0.87%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- +6.71%
- +13.32%
- 1Y return
- -75.96%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IBO
- SEC Form S-8 POS filed by Impact BioMedical Inc.
- SEC Form S-8 POS filed by Impact BioMedical Inc.
- Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
- SEC Form 4 filed by Macko Todd D
- SEC Form 4 filed by Grady Jason
- SEC Form 10-K filed by Impact BioMedical Inc.
- Impact BioMedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Large owner Dss, Inc. sold $88,006 worth of shares (161,000 units at $0.55), decreasing direct ownership by 23% to 545,024 units (SEC Form 4)
- SEC Form DEF 14C filed by Impact BioMedical Inc.
- SEC Form PRE 14C filed by Impact BioMedical Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S